Brokerages expect Halyard Health Inc (NYSE:HYH) to report earnings per share (EPS) of $0.49 for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Halyard Health’s earnings, with the lowest EPS estimate coming in at $0.47 and the highest estimate coming in at $0.51. Halyard Health reported earnings of $0.50 per share in the same quarter last year, which would indicate a negative year over year growth rate of 2%. The company is expected to issue its next quarterly earnings report before the market opens on Tuesday, February 27th.
According to Zacks, analysts expect that Halyard Health will report full year earnings of $2.08 per share for the current fiscal year, with EPS estimates ranging from $2.06 to $2.09. For the next year, analysts forecast that the business will report earnings of $2.14 per share, with EPS estimates ranging from $2.01 to $2.27. Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Halyard Health.
HYH has been the topic of several research reports. TheStreet cut Halyard Health from a “b-” rating to a “c+” rating in a report on Monday, October 30th. Stifel Nicolaus restated a “buy” rating and set a $52.00 price target on shares of Halyard Health in a report on Friday, November 3rd. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. Finally, Zacks Investment Research upgraded Halyard Health from a “hold” rating to a “buy” rating and set a $53.00 price target on the stock in a report on Wednesday, December 6th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Halyard Health presently has an average rating of “Buy” and a consensus price target of $49.00.
A number of hedge funds have recently made changes to their positions in the stock. MetLife Investment Advisors LLC bought a new stake in Halyard Health in the fourth quarter valued at approximately $2,332,000. Macquarie Group Ltd. boosted its holdings in Halyard Health by 103.0% in the fourth quarter. Macquarie Group Ltd. now owns 859,281 shares of the medical instruments supplier’s stock valued at $39,681,000 after acquiring an additional 435,935 shares during the last quarter. Vident Investment Advisory LLC boosted its holdings in Halyard Health by 6.5% in the fourth quarter. Vident Investment Advisory LLC now owns 67,997 shares of the medical instruments supplier’s stock valued at $3,140,000 after acquiring an additional 4,147 shares during the last quarter. Jane Street Group LLC boosted its holdings in Halyard Health by 88.0% in the fourth quarter. Jane Street Group LLC now owns 8,808 shares of the medical instruments supplier’s stock valued at $407,000 after acquiring an additional 4,124 shares during the last quarter. Finally, LPL Financial LLC bought a new stake in Halyard Health in the fourth quarter valued at approximately $206,000. Institutional investors and hedge funds own 88.73% of the company’s stock.
Halyard Health (NYSE HYH) traded down $0.04 during trading hours on Friday, hitting $47.51. The stock had a trading volume of 246,117 shares, compared to its average volume of 336,202. The company has a market capitalization of $2,225.18, a PE ratio of 39.92, a P/E/G ratio of 2.49 and a beta of 1.71. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.19 and a current ratio of 2.13. Halyard Health has a 52 week low of $35.24 and a 52 week high of $50.99.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/18/0-49-eps-expected-for-halyard-health-inc-hyh-this-quarter.html.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Get a free copy of the Zacks research report on Halyard Health (HYH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.